XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.2
REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES
 6 Months Ended
Jun. 30, 2024
Noncontrolling Interest [Abstract]  
REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES
Certain of our investees’ partnership and operating agreements contain terms that, upon the occurrence of specified events, could obligate us to purchase some or all of the noncontrolling interests related to our consolidated subsidiaries. The noncontrolling interests subject to these provisions, and the income attributable to those interests, are not included as part of our equity and are presented as redeemable noncontrolling interests in the accompanying Condensed Consolidated Balance Sheets at June 30, 2024 and December 31, 2023.
The following table presents the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries for the periods presented:
 Six Months Ended June 30,
 20242023
Balances at beginning of period $2,391 $2,149 
Net income222 167 
Distributions paid to noncontrolling interests(175)(143)
Purchases and sales of businesses and noncontrolling interests, net375 104 
Balances at end of period $2,813 $2,277 
The following tables present the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests:
 June 30, 2024December 31, 2023
Hospital Operations$910 $860 
Ambulatory Care1,903 1,531 
Redeemable noncontrolling interests$2,813 $2,391 
 Six Months Ended June 30,
 20242023
Hospital Operations$53 $44 
Ambulatory Care169 123 
Net income available to redeemable noncontrolling interests$222 $167 
In June 2022, we entered into a share purchase agreement to acquire the 5% ownership interest then-held by Baylor University Medical Center (“Baylor”) in USPI for $406 million. Under the share purchase agreement, we are obligated to make non-interest-bearing monthly payments of approximately $11 million through June 2025. At June 30, 2024, the remaining obligation under the share purchase agreement of $133 million was classified as a current liability and included in other current liabilities in the accompanying Condensed Consolidated Balance Sheet. At December 31, 2023, we had a liability of $135 million recorded in other current liabilities for the purchase of Baylor’s ownership interest and $63 million recorded in other long‑term liabilities in the accompanying Condensed Consolidated Balance Sheet.